BCR-ABL1 F317L
|
CML
|
BCR-ABL1 F317L
|
CML
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
CML
|
BCR-ABL1 F317L
|
CML
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
CML
|
BCR-ABL1 F317L
|
CML
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BCR-ABL1 F317L
|
ALL
|
BCR-ABL1 F317L
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
ALL
|
BCR-ABL1 F317L
|
ALL
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BCR-ABL1 F317L
|
ALL
|
BCR-ABL1 F317L
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
CML
|
BCR-ABL1 F317L
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
BCR-ABL1 F317L
|
CML
|
BCR-ABL1 F317L
|
CML
|
dasatinib + imatinib Resistant: D – Preclinical
|
dasatinib + imatinib Resistant: D – Preclinical
|